COMPREHENSIVE ACCESS AND SUPPORT

Covered at the preferred brand tier for more* patients than any other DOAC1

FORMULARY COVERAGE WITH XARELTO®

Janssen is dedicated to making XARELTO® affordable and accessible for all patients. XARELTO® is widely accessible nationwide with preferred coverage for 95% of commercial and >95% of Medicare Part D patients.1

To see the formulary coverage for your patients, enter your ZIP code. Your results will appear below.

This percentage may not represent 100% of formulary lives due to data limitations.

The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. It is not intended to increase or maximize reimbursement by any payer. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. Please contact the plan for more information about coverage or any restrictions or prerequisites that may apply. We strongly recommend you consult the payer organization for its reimbursement policies. All information is subject to change.

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*“More” means that there is an absolute difference in percentage of lives greater than or equal to ±5%.

Reference: 1. Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of March 2020. Collected on March 11, 2020. 2. Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of June 2020. Collected on June 30, 2020.

DOAC=direct oral anticoagulant.

JANSSEN CAREPATH FOR XARELTO®

Janssen CarePath
Provider Portal

SIGN UP LOG IN

  • Benefits investigations & prior authorizations
  • Enroll eligible patients in Savings Program
  • View Savings Program transactions

Prescription fills as low as $10 every fill* for eligible patients with commercial or private insurance
  • Eligible patients with an approved chronic indication for XARELTO®
  • Eligible patients using commercial or private insurance can save on out-of-pocket costs for XARELTO®. Depending on the health insurance plan, savings may apply toward co-pay, co-insurance, or deductible. Eligible commercial patients pay $10 per fill for XARELTO® (up to a 90-day fill), subject to program benefit limits. There is no limit to this benefit for the first 90 days, inclusive of the starter kit, and then a $200 limit for each 30-day supply thereafter. There is a $3,400 maximum program benefit per calendar year
  • Not valid for patients using Medicare, Medicare Part D, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement

See full eligibility requirements.

SUPPORT FOR PATIENTS USING GOVERNMENT INSURANCE OR PATIENTS WITHOUT INSURANCE COVERAGE

JANSSEN PRESCRIPTION ASSISTANCE FOR XARELTO®

  • Provides information on affordability options including information about independent foundations that may have available funding to help minimize drug costs for XARELTO®

For more information, visit Janssen Prescription Assistance.

OTHER RESOURCES

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 1-800-652-6227 (9 AM to 6 PM ET) or visit the foundation website at www.JJPAF.org.

*Fill medication up to 90 days.